Challenges for patient selection with VEGF inhibitors R. LongoG. Gasparini Review 17 March 2007 Pages: 151 - 170
Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine Timothy H. MarczyloRichard D. VerschoyleAndreas J. Gescher Original Article 19 October 2006 Pages: 171 - 177
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins Attaphol PawarodeSuneet ShuklaMaria R. Baer Original Article 10 October 2006 Pages: 179 - 188
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy Kiyoshi MoriYukari KamiyamaTetsuro Kodama Original Article 10 November 2006 Pages: 189 - 195
Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models Hong Sub LeeJung Su RyuTae-Yong Kim Original Article 10 November 2006 Pages: 197 - 201
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors A. C. LockhartR. BukowskiA. X. Zhu Original Article 08 November 2006 Pages: 203 - 209
The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer Linrun WangXiuhua WuJian Liu Original Article 24 November 2006 Pages: 211 - 218
Induction of oxidative damage by copper-based antineoplastic drugs (Casiopeínas®) Radamés Alemón-MedinaMatilde Breña-ValleLena Ruiz-Azuara Original Article 08 February 2007 Pages: 219 - 228
Antitumor activity of edotecarin in breast carcinoma models Marina CiomeiValter CrociEnrico Pesenti Original Article 07 November 2006 Pages: 229 - 235
Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes Won-Kyu KimYoung-Ee Kwon Original Article 07 November 2006 Pages: 237 - 243
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status Hans MindermanYunfei ZhouMaria R. Baer Original Article 10 November 2006 Pages: 245 - 255
Tissue distribution in mice and metabolism in murine and human liver of apigenin and tricin, flavones with putative cancer chemopreventive properties Hong CaiDavid J. BoocockAndreas J. Gescher Original Article 07 November 2006 Pages: 257 - 266
Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer Takashi HiroseTakao ShiraiMitsuru Adachi Original Article 02 February 2007 Pages: 267 - 274
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo Anthony TumberLaura S. CollinsJames W. A. Ritchie Original Article 24 November 2006 Pages: 275 - 283
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses Kenji TamuraKazuhiko NakagawaMasahiro Fukuoka Original Article 30 November 2006 Pages: 285 - 293
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial Tomislav DragovichMark HubermanAmita Patnaik Clinical Trial Report 06 December 2006 Pages: 295 - 303
Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect F. PuissetE. ChatelutH. Roché Short Communication 24 November 2006 Pages: 305 - 308
